OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data
Simona Guerzoni, Carlo Baraldi, Umberto Pensato, et al.
Neurological Sciences (2022) Vol. 43, Iss. 6, pp. 3823-3830
Closed Access | Times Cited: 16
Simona Guerzoni, Carlo Baraldi, Umberto Pensato, et al.
Neurological Sciences (2022) Vol. 43, Iss. 6, pp. 3823-3830
Closed Access | Times Cited: 16
Showing 16 citing articles:
Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data
Antun R. Pavelić, Christian Wöber, Franz Riederer, et al.
Cells (2022) Vol. 12, Iss. 1, pp. 143-143
Open Access | Times Cited: 38
Antun R. Pavelić, Christian Wöber, Franz Riederer, et al.
Cells (2022) Vol. 12, Iss. 1, pp. 143-143
Open Access | Times Cited: 38
Impact of multiple treatment cycles with anti-CGRP monoclonal antibodies on migraine course: focus on discontinuation periods. Insights from the multicenter, prospective, I-GRAINE study
Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.
Journal of Neurology (2024) Vol. 271, Iss. 5, pp. 2605-2614
Open Access | Times Cited: 7
Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.
Journal of Neurology (2024) Vol. 271, Iss. 5, pp. 2605-2614
Open Access | Times Cited: 7
Methodological considerations on real-world evidence studies of monoclonal antibodies against the CGRP-pathway for migraine: a systematic review
Nicolas Vandenbussche, Karolina Pisarek, Koen Paemeleire
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 12
Nicolas Vandenbussche, Karolina Pisarek, Koen Paemeleire
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 12
Three-year treatment with anti-CGRP monoclonal antibodies modifies migraine course: the prospective, multicenter I-GRAINE study
Piero Barbanti, Cinzia Aurilia, Paola Torelli, et al.
Journal of Neurology (2025) Vol. 272, Iss. 2
Open Access
Piero Barbanti, Cinzia Aurilia, Paola Torelli, et al.
Journal of Neurology (2025) Vol. 272, Iss. 2
Open Access
Real-world effectiveness and safety of erenumab for the treatment of migraine: A systematic review and meta-analysis
Jaime Fernández-Bravo-Rodrigo, Iván Cavero‐Redondo, Maribel Lucerón‐Lucas‐Torres, et al.
European Journal of Pharmacology (2024) Vol. 976, pp. 176702-176702
Closed Access | Times Cited: 3
Jaime Fernández-Bravo-Rodrigo, Iván Cavero‐Redondo, Maribel Lucerón‐Lucas‐Torres, et al.
European Journal of Pharmacology (2024) Vol. 976, pp. 176702-176702
Closed Access | Times Cited: 3
Revolutionizing migraine management: advances and challenges in CGRP-targeted therapies and their clinical implications
Aynur Özge, Betül Baykan, Şebnem Bıçakçı, et al.
Frontiers in Neurology (2024) Vol. 15
Open Access | Times Cited: 3
Aynur Özge, Betül Baykan, Şebnem Bıçakçı, et al.
Frontiers in Neurology (2024) Vol. 15
Open Access | Times Cited: 3
Potential Predictors of Response to CGRP Monoclonal Antibodies in Chronic Migraine: Real-World Data
Carmen Sánchez-Rodríguez, Ana Beatriz Gago‐Veiga, David García‐Azorín, et al.
Current Pain and Headache Reports (2023)
Closed Access | Times Cited: 7
Carmen Sánchez-Rodríguez, Ana Beatriz Gago‐Veiga, David García‐Azorín, et al.
Current Pain and Headache Reports (2023)
Closed Access | Times Cited: 7
[Artículo traducido] Análisis del retratamiento con anticuerpos monoclonales en la migraña crónica/episódica: datos en vida real
Patricia García-Lloret, Mercedes Galván-Banqueri, María de las Aguas Robustillo Cortés, et al.
Farmacia Hospitalaria (2024) Vol. 48, Iss. 4, pp. T176-T179
Open Access | Times Cited: 2
Patricia García-Lloret, Mercedes Galván-Banqueri, María de las Aguas Robustillo Cortés, et al.
Farmacia Hospitalaria (2024) Vol. 48, Iss. 4, pp. T176-T179
Open Access | Times Cited: 2
Monoclonal Antibodies Against Calcitonin Gene-related Peptide for Migraine Prophylaxis: A Systematic Review of Real-world Data
Antun R. Pavelić, Christian Wöber, Franz Riederer, et al.
(2022)
Open Access | Times Cited: 9
Antun R. Pavelić, Christian Wöber, Franz Riederer, et al.
(2022)
Open Access | Times Cited: 9
The ultimate guide to the anti-CGRP monoclonal antibodies galaxy
Davide Mascarella, Eleonora Matteo, Valentina Favoni, et al.
Neurological Sciences (2022) Vol. 43, Iss. 9, pp. 5673-5685
Closed Access | Times Cited: 8
Davide Mascarella, Eleonora Matteo, Valentina Favoni, et al.
Neurological Sciences (2022) Vol. 43, Iss. 9, pp. 5673-5685
Closed Access | Times Cited: 8
Chronic Migraine as a Primary Chronic Pain Syndrome and Recommended Prophylactic Therapeutic Options: A Literature Review
Délia Szok, Anett Csáti, László Vécsei, et al.
Life (2023) Vol. 13, Iss. 3, pp. 665-665
Open Access | Times Cited: 3
Délia Szok, Anett Csáti, László Vécsei, et al.
Life (2023) Vol. 13, Iss. 3, pp. 665-665
Open Access | Times Cited: 3
Konsensusstatement der Migräne- und Kopfschmerzgesellschaften (DMKG, ÖKSG & SKG) zur Therapiedauer der medikamentösen Migräneprophylaxe
Gudrun Goßrau, Stefanie Förderreuther, Ruth Ruscheweyh, et al.
Der Nervenarzt (2022) Vol. 94, Iss. 4, pp. 306-317
Open Access | Times Cited: 5
Gudrun Goßrau, Stefanie Förderreuther, Ruth Ruscheweyh, et al.
Der Nervenarzt (2022) Vol. 94, Iss. 4, pp. 306-317
Open Access | Times Cited: 5
Migraine Disability and Severity Improvement during Long-Term Treatment with Erenumab
Marco Bolchini, Francesca Schiano di Cola, Giulia Ceccardi, et al.
European Neurology (2022) Vol. 86, Iss. 2, pp. 135-139
Closed Access | Times Cited: 4
Marco Bolchini, Francesca Schiano di Cola, Giulia Ceccardi, et al.
European Neurology (2022) Vol. 86, Iss. 2, pp. 135-139
Closed Access | Times Cited: 4
Analysis of retreatment with monoclonal antibodies in chronic/episodic migraine: Real world data
Patricia García-Lloret, Mercedes Galván-Banqueri, María de las Aguas Robustillo Cortés, et al.
Farmacia Hospitalaria (2024) Vol. 48, Iss. 4, pp. 176-179
Open Access
Patricia García-Lloret, Mercedes Galván-Banqueri, María de las Aguas Robustillo Cortés, et al.
Farmacia Hospitalaria (2024) Vol. 48, Iss. 4, pp. 176-179
Open Access
Konsensusstatement der Migräne- und Kopfschmerzgesellschaften (DMKG, ÖKSG & SKG) zur Therapiedauer der medikamentösen Migräneprophylaxe
Gudrun Goßrau, Stefanie Förderreuther, Ruth Ruscheweyh, et al.
Der Schmerz (2022) Vol. 37, Iss. 1, pp. 5-16
Open Access | Times Cited: 2
Gudrun Goßrau, Stefanie Förderreuther, Ruth Ruscheweyh, et al.
Der Schmerz (2022) Vol. 37, Iss. 1, pp. 5-16
Open Access | Times Cited: 2
Indikationsgerechter Einsatz monoklonaler Antikörper bei Migräne
Jörg Hohmann
NeuroTransmitter (2022) Vol. 33, Iss. 6, pp. 26-31
Closed Access
Jörg Hohmann
NeuroTransmitter (2022) Vol. 33, Iss. 6, pp. 26-31
Closed Access
